/ Pack :
1 X 10's
/ Type :
Dapagliflozin is in a class of drug called SGLT2 inhibitors that works by targeting and helping to stop sodium-glucose transport proteins from allowing glucose that has been filtered out of the blood by the kidneys to be reabsorbed back into the blood.
The SGLT2 proteins are responsible for 90% of the glucose that is reabsorbed into the blood. By inhibiting the SGLT2 proteins. Dapagliflozin allows a significant amount of glucose in the blood to be removed by the kidneys and excreted in the urine.
SGLT2i have moderate benefits on atherosclerotic major adverse cardiovascular events that seem confined to patients with established atherosclerotic cardiovascular disease. However, they have robust benefits on reducing hospitalisation for heart failure and progression of renal disease regardless of existing atherosclerotic cardiovascular disease or a history of heart failure - The Lancet, Vol.- 393, Iss.-10166, p31-39.
View more products with following salts